NexImmune Bolsters Leadership Team Adding Former MedImmune Executive as Chief Financial Officer
GAITHERSBURG, Md., Jan. 09, 2020 (Excerpts below were originally published on GLOBE NEWSWIRE)
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veteran John Trainer, MBA has been appointed as the Company’s Financial Officer. Additionally, Han Myint, MD has been appointed as the Chief Medical Officer.
Mr. Trainer commented, “The tremendous potential of the NexImmune AIM platform in multiple types of cancer and other disease areas represents a significant growth opportunity for the Company. Scaling up and financing this growth through additional capital raises, partnerships and a potential IPO will be a top priority for us moving forward. I’m excited to be a part of the NexImmune team as we push forward on our mission to help patients.”
Mr. Trainer most recently served as Vice President and Head of Partnering & Strategy for MedImmune, the biologics-focused R&D unit of AstraZeneca. There, he led all in-licensing, out-licensing and collaboration work for MedImmune including such transactions as the spin-out of Viela Bio (which raised a $250m Series A). Mr. Trainer was also responsible for working with partners such as Johns Hopkins University and the NIH to help develop promising new companies and technologies. Previous to that role, Mr. Trainer was Vice President, Corporate Development for AstraZeneca and the commercial leader for AstraZeneca’s Infection, Neuroscience and Gastrointestinal group globally, as well as holding a variety of financial, transactional and commercial roles at MedImmune. He received his MBA from Harvard Business School and his undergraduate degree from Harvard College.
Scott Carmer, President, and CEO of NexImmune, commented on the additions to the Company’s Executive Leadership Team, “I am thrilled to have both Han and John join our team. Individually, each is a highly respected and accomplished industry leader. Together, their combined experience, expertise and leadership will be a strong complement to those of our existing executive team. As we initiate our first clinical trials in 1Q2020, NexImmune is now poised to exploit the full potential of our unique technology platform for the benefit of patients in need.”
NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on the proprietary Artificial Immune Modulation (AIM) nanotechnology platform. The AIM platform enables the ability to expand multi-antigen specific T cells with enhanced anti-tumor properties without the need for genetic manipulation. NexImmune is leveraging the AIM technology platform to develop a pipeline of products to treat cancer and auto-immune diseases.
Latest posts by Chris Frew (see all)
- NASDAQ #TradeTalks Interview with Adaptive Phage Therapeutics CEO: Fighting Antibiotic Resistance with Phage Therapy - January 14, 2020
- New Immuno-Oncology Startup out of Baltimore Launches at JPM Healthcare Conference with Veteran Board, Advisors and Officers - January 14, 2020
- These Industry-Leading Companies & Experts Are Presenting at the Phacilitate World Stem Cell Summit - January 14, 2020